News
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
FEATURED STORIES
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Takeda will present nine abstracts at the annual ASH meeting, including data for its hemophilia program, as well as announcing a new sickle cell disease program.
BeiGene raised $3.3 billion on Shanghai’s STAR market, making it the first company to trade its shares in Shanghai, Hong Kong, and New York.
BrainStorm Cell Therapeutics is making a strong comeback after the FDA was a little impressed with Phase III results of amyotrophic lateral sclerosis treatment.
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
Halberd announced that preliminary testing of its extracorporeal laser irradiation methodologies completely eradicated Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF).
The collaboration covers the co-development and co-commercialization of products created from Foghorn’s BRM oncology program and another oncology target.
Arena Pharmaceuticals’ share price nearly doubled in premarket trading after Pfizer announced it was acquiring the company and its diverse portfolio of developmental and clinical assets.
Novartis is going full steam ahead with its cancer development efforts, recently posting positive results from two ongoing trials for lymphoma and leukemia.
Orca-T demonstrated significantly higher graft-versus-host disease-free, relapse-free survival (GRFS) rates compared to patients who received standard of care.
The following features are highlights from the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in-person in Atlanta, GA, and virtually from December 11 to 14.